PB 39 of 2018

 

National Health (Pharmaceutical Benefits – early supply) Amendment Instrument 2018 (No. 5)

 

National Health Act 1953

___________________________________________________________________________

 

I, LISA LA RANCE, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

 

Dated  29 May 2018

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LISA LA RANCE

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health


___________________________________________________________________________

1               Name of Instrument

(1)           This Instrument is the National Health (Pharmaceutical Benefits – early supply) Amendment Instrument 2018 (No. 5).

(2)           This Instrument may also be cited as PB 39 of 2018.

2               Commencement

This Instrument commences on 1 June 2018.

3               Amendment of National Health (Pharmaceutical Benefits—early supply) Instrument 2015 (PB 120 of 2015)

Schedule 1 amends the National Health (Pharmaceutical Benefits—early supply) Instrument 2015 (PB 120 of 2015).

 

Schedule 1  Amendments

[1]           Schedule 1, after entry for Cabergoline in the form Tablet 2 mg

insert:

Cabozantinib

Tablet 20 mg

20

30

2

 

Cabozantinib

Tablet 20 mg

20

30

5

 

Cabozantinib

Tablet 40 mg

20

30

2

 

Cabozantinib

Tablet 40 mg

20

30

5

 

Cabozantinib

Tablet 60 mg

20

30

2

 

Cabozantinib

Tablet 60 mg

20

30

5

 

[2]           Schedule 1, omit entry for Daclizumab

[3]           Schedule 1, after entry for Donepezil in the form Tablet containing donepezil hydrochloride 5 mg

insert:

Dulaglutide

Injection 1.5 mg in 0.5 mL single dose pre-filled pen

20

4

5

 

[4]           Schedule 1, after entry for Flutamide

insert:

Fluticasone furoate with umeclidinium and vilanterol

Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenatate) per dose, 30 doses

20

1

5

 

[5]           Schedule 1, after entry for Golimumab in the form Injection 50 mg in 0.5 mL single use pre filled syringe

insert:

Golimumab

Injection 100 mg in 1 mL single use pre-filled pen

20

1

5